4.5 Article

Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis

Journal

MEDICINE
Volume 94, Issue 40, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MD.0000000000001692

Keywords

-

Ask authors/readers for more resources

Reactive hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition related to a cytokine storm leading to multiorgan dysfunction. A better understanding of coagulation disorders, frequently reported in HLH patients, may improve outcomes.Critically ill HLH patients managed in a multidisciplinary national reference center were retrospectively included. Relationships between coagulation disorders, severe bleedings, and outcomes were assessed.One hundred and seventeen patients fulfilled the HLH 2004 criteria. The most common HLH etiology was hematologic conditions (73%), followed by infectious diseases (20%), systemic rheumatic diseases (5%), and undetermined HLH etiology (3%). All patients exerted thrombocytopenia. Coagulation disorders were diagnosed in 79 (68%) patients (61 had hypofibrinogenemia<1.5g/L, 51 had prothrombin time [PT]<50%). The worst median value throughout ICU stay was 52% (38-65) for PT with a factor V level of 35% (27-43), 1.59 (1.30-2.09) for the activated partial thromboplastin time (APTT) ratio, and 2.33g/L (1.13-3.86) for the fibrinogen level. Disseminated intravascular coagulation (DIC) was found in 50% of patients. Coagulation disorders were more frequent in immunocompromised patients, those with histological/cytological feature of hemophagocytosis, those with the highest ferritin concentrations, and in patients with HLH not related to infection. These patients were more prone to receive mechanical ventilation, vasopressors, or renal replacement therapy. Twenty-six (22%) patients presented severe bleeding complications, including 5 patients dying from hemorrhagic shock. Strikingly, the only coagulation parameter significantly associated with severe bleeding was low fibrinogen with a cutoff value of 2g/L (P=0.03). Overall, 33 (28%) patients died in the ICU and hospital mortality was 44%. Coagulation disorders were associated with higher mortality, especially fibrinogen<2g/L (P=0.04) and PT value (P=0.03). The occurrence of bleeding complications was not associated with higher risk of hospital death. Risk factors associated with mortality by multivariate analysis were fibrinogen level<2g/L (OR 2.42 [1.08-5.41]), SOFA score>6 (OR 3.04 [1.32-6.98]), and age>46 years (OR 2.26 [1.02-5.04]).Up to two-third of critically ill HLH patients present with coagulation disorders. Hypofibrinogenemia or DIC was found in half of the patients and low PT in 40%. These patients require more life support and have a higher mortality rate. Fibrinogen <2g/L is associated with the occurrence of severe bleeding and mortality.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Hematology

Efficacy of subcutaneous preemptive rituximab in immune-mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases

Maxime Delrue, Minh Tam Baylatry, Anne-Christine Joly, Elise Corre, Zora Marjanovic, Noujoud El-Khoury-Hanna, Frederic Feger, Ludovic Suner, Agnes Veyradier, Alain Stepanian, Paul Coppo

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Article Oncology

Diagnostic strategy for trigger identification in severe reactive hemophagocytic lymphohistiocytosis: A diagnostic accuracy study

Jean-Jacques Tudesq, Sandrine Valade, Lionel Galicier, Lara Zafrani, David Boutboul, Cedric de Bazelaire, Nicolas Munoz-Bongrand, Emmanuel Canet, Fanny Ardisson, Virginie Lemiale, Michael Darmon, Elie Azoulay, Eric Mariotte

Summary: Management of reactive hemophagocytic lymphohistiocytosis (rHLH) requires early recognition, identification of triggers, and adequate treatment to reduce mortality. Tissue biopsies have a high diagnostic yield in identifying triggers in severe rHLH cases. While splenectomy carries a procedural risk, it can be reserved for cases where diagnostic uncertainty persists. Early initiation of appropriate therapy based on trigger identification leads to better outcomes in patients with rHLH.

HEMATOLOGICAL ONCOLOGY (2021)

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine, Xavier Mariette, Pierre-Louis Tharaux, Matthieu Resche-Rigon, Raphael Porcher, Philippe Ravaud

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

Letter Hematology

Aggressive lymphoma, hemophagocytic lymphohistiocytosis, and G6PD crisis: a lytic cocktail

Pierre-Edouard Debureaux, Mathilde Ruggiu, Stephanie Mathis, Adrien Mirouse, Bedis Dhouaieb, Wendy Cuccuini, Jean Soulier, Eric Mariotte, Pierre Lemaire

ANNALS OF HEMATOLOGY (2022)

Letter Hematology

The clinical picture of thrombotic microangiopathy in patients older than 60 years of age

Julien Schmidt, Lara Zafrani, Virginie Lemiale, Alain Stepanian, Berangere Joly, Elie Azoulay, Eric Mariotte

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Article Critical Care Medicine

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Xavier Mariette, Olivier Hermine, Pierre Louis Tharaux, Matthieu Resche-Rigon, Raphael Porcher, Philippe Ravaud, Serge Bureau, Maxime Dougados, Annick Tibi

Summary: The study aimed to determine the effectiveness of anakinra in improving outcomes of patients with mild-to-moderate COVID-19 pneumonia, but the results showed that anakinra did not show improvement in patient outcomes. Further studies are needed to assess the efficacy of anakinra in other selected groups of patients with more severe COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

Article Critical Care Medicine

Prior Exposure to Angiotensin II Receptor Blockers in Patients With Septic Shock to Individualize Mean Arterial Pressure Target? A Post Hoc Analysis of the Sepsis and Mean Arterial Pressure (SEPSISPAM) Trial*

Julien Demiselle, Valerie Seegers, Marie Lemerle, Ferhat Meziani, Fabien Grelon, Bruno Megarbane, Nadia Anguel, Jean-Paul Mira, Pierre-Francois Dequin, Soizic Gergaud, Nicolas Weiss, Francois Legay, Yves Le Tulzo, Marie Conrad, Rene Robert, Frederic Gonzalez, Christophe Guitton, Fabienne Tamion, Jean-Marie Tonnelier, Jean-Pierre Bedos, Thierry Van der Linden, Antoine Vieillard-Baron, Eric Mariotte, Gael Pradel, Olivier Lesieur, Jean-Damien Ricard, Fabien Herve, Damien du Cheyron, Claude Guerin, Jean-Louis Teboul, Julie Helms, Peter Radermacher, Pierre Asfar

Summary: The SEPSISPAM trial found that targeting high mean arterial pressure may reduce acute kidney injury in septic shock patients with chronic hypertension, and post hoc analysis showed that chronic hypertensive patients treated with angiotensin II receptor blocker might benefit from a high mean arterial pressure target to reduce the risk of acute kidney injury.

CRITICAL CARE MEDICINE (2021)

Article Hematology

Performance of Diagnostic Scores in Thrombotic Microangiopathy Patients in the Intensive Care Unit: A Monocentric Study

Eric Mariotte, Lara Zafrani, Jehane Fadlallah, Lionel Galicier, Etienne Ghrenassia, Lionel Kerhuel, Laure Calvet, Audrey De Jong, Virginie Lemiale, Sandrine Valade, Berangere S. Joly, Alain Stepanian, Elie Azoulay, Michael Darmon

Summary: This study evaluated the accuracy of diagnostic scores for thrombotic thrombocytopenic purpura (TTP) in an intensive care unit (ICU) setting, finding that platelet count could be similarly used to differentiate TTP from non-TTP patients as the Coppo score.

THROMBOSIS AND HAEMOSTASIS (2021)

Article Virology

Accessible LAMP-Enabled Rapid Test (ALERT) for Detecting SARS-CoV-2

Ali Bektas, Michael F. Covington, Guy Aidelberg, Anibal Arce, Tamara Matute, Isaac Nunez, Julia Walsh, David Boutboul, Constance Delaugerre, Ariel B. Lindner, Fernan Federici, Anitha D. Jayaprakash

Summary: The COVID-19 pandemic has highlighted the challenges in large-scale testing, leading to the development of a DIY workflow for rapid and accurate detection of viral RNA with high sensitivity and specificity. This method improves efficiency and accuracy of testing through various techniques, allowing for quick testing at home or in healthcare settings.

VIRUSES-BASEL (2021)

Article Microbiology

Cutaneous Granulomatosis Revealing Whipple's Disease: Value of Tropheryma whipplei Polymerase Chain Reaction Assay for the Diagnosis

Souheil Zayet, Pierre Isnard, Jacinta Bustamante, David Boutboul, Sarra Abroug, Nabil Belfeki

Summary: Whipple's Disease is a rare systemic infectious disease caused by the ubiquitous actinomycetes Tropheryma whipplei. This report describes a rare case of cutaneous granulomatosis with hypercalcemia as an unusual presenting feature of Whipple's disease. Treatment with hydroxychloroquine and doxycycline resulted in rapid resolution of symptoms and complete recovery.

PATHOGENS (2021)

Article Immunology

Gain-of-function IKZF1 variants in humans cause immune dysregulation associated with abnormal T/B cell late differentiation

Akihiro Hoshino, David Boutboul, Yuan Zhang, Hye Sun Kuehn, Jerome Hadjadj, Nihal Ozdemir, Tiraje Celkan, Christoph Walz, Capucine Picard, Christelle Lenoir, Nizar Mahlaoui, Christoph Klein, Xiao Peng, Antoine Azar, Erin Reigh, Morgane Cheminant, Alain Fischer, Frederic Rieux-Laucat, Isabelle Callebaut, Fabian Hauck, Joshua Milner, Sergio D. Rosenzweig, Sylvain Latour

Summary: This study identified IKZF1 variants in the DNA binding domain that cause inflammatory, autoimmune, allergic symptoms, and abnormal plasma cell proliferation. These variants act as gain-of-function alleles, leading to increased gene expression associated with T(H)2 and plasma cell differentiation. Treatment with Lenalidomide can correct these abnormalities.

SCIENCE IMMUNOLOGY (2022)

Letter Hematology

Mantle cell lymphoma in human immunodeficiency virus-infected patients

Remi Bertinchamp, Margaux Garzaro, David Boutboul, Lionel Galicier, Veronique Meignin, Julien Calvani, Mohammed El Hadi Djerad, Willy Rozenbaum, Philippe Simon, Eric Oksenhendler, Laurence Gerard

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Hematology

Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+multicentric Castleman disease

Camille Rasmussen, Laurence Gerard, Jehane Fadlallah, Emilie Corvilain, Lionel Galicier, Veronique Meignin, Eric Oksenhendler, David Boutboul

Summary: This retrospective study analyzed the treatment outcome of 99 HHV8(+) MCD patients with rituximab-based therapy. The study found that HIV- status, high HHV8 viral load, and elevated serum CRP levels were independent risk factors for disease progression after rituximab-induced complete remission. The study also suggested that HIV+ patients had a lower progression rate, possibly due to immune restoration upon antiretroviral therapy.

BLOOD ADVANCES (2023)

Editorial Material Clinical Neurology

Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement

Cyrille Coustal, Radjiv Goulabchand, Pierre Labauge, Philippe Guilpain, Clarisse Carra-Dalliere, Edouard Januel, Eric Jeziorski, Valery Salle, Jean-Francois Viallard, David Boutboul, Claire Fieschi, Delphine Gobert, Nathalie Aladjidi, Patricia Rullier, Julie Graveleau, Marie Piel-Julian, Felipe Suarez, Benedicte Neven, Nizar Mahlaoui, Xavier Ayrignac

Summary: Neurologic involvement is common among patients with CTLA4 deficiency, with symptoms such as headaches, focal deficit, and seizures. MRI results show contrast-enhancing lesions reminiscent of multiple sclerosis. Abatacept treatment has shown good clinical and radiologic response in these patients.

NEUROLOGY (2023)

No Data Available